SBIOETF / FundALPS Medical Breakthroughs ETF
Verdicts genuinely change. Free email alert the moment SBIO's does — no target price to set, unlike a price alert.
Whether this fund clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
ALPS Medical Breakthroughs ETF ETF · ALPS ETF TRUST
110 holdings · as of 2026-08-31 (2.6 months ago)
NON-COMPLIANT At least 34.89% of portfolio weight is in non-compliant holdings — already over the 5% threshold, so the verdict is settled whatever the unmatched 53% turns out to be. Matching more holdings can only raise this share, never lower it.
110 holdings, 72 matched (47% of weight). Portfolio as of 2026-08-31, filed 2026-10-29. Source: SEC Form N-PORT.
11.19% of this portfolio’s income is non-permissible — weighted across holdings, computed over 28% of portfolio weight (36 of 110 holdings). The common approach purifies that proportion of income received — dividends — not of the position’s value. We report the ratio; what to do with it is a question for your own scholar.
Portfolio shares are withheld: coverage is below the floor needed to state one. The holdings themselves are below, because the names are evidence you can check.
All holdings (110)
| Holding | Status | Weight | Every methodology, and the debt ratio behind it |
|---|---|---|---|
| Crinetics Pharmaceuticals Inc | UNSCREENED | 4.60% | no in-house ratios for this holding |
| Apogee Therapeutics Inc | UNSCREENED | 4.29% | no in-house ratios for this holding |
| Cg Oncology Inc | UNSCREENED | 3.41% | no in-house ratios for this holding |
| TVTX Travere Therapeutics Inc | COMPLIANT | 3.16% | AAOIFI10.0% Usmani77.2% Dow Jones Islamic24.4% S&P Shariah32.6% MSCI Islamic77.2% MSCI Islamic M-Series32.6% FTSE Shariah75.4% |
| Xenon Pharmaceuticals Inc | UNSCREENED | 2.99% | no in-house ratios for this holding |
| Dianthus Therapeutics Inc | UNSCREENED | 2.96% | no in-house ratios for this holding |
| Oruka Therapeutics Inc | UNSCREENED | 2.87% | no in-house ratios for this holding |
| ACAD Acadia Pharmaceuticals Inc | COMPLIANT | 2.54% | AAOIFI2.3% Usmani4.0% Dow Jones Islamic1.9% S&P Shariah2.0% MSCI Islamic4.0% MSCI Islamic M-Series2.0% FTSE Shariah0.0% |
| Edgewise Therapeutics Inc | UNSCREENED | 2.31% | no in-house ratios for this holding |
| Definium Therapeutics Inc | UNSCREENED | 2.23% | no in-house ratios for this holding |
| DYN Dyne Therapeutics Inc | NON_COMPLIANT | 2.16% | AAOIFI7.0% Usmani17.7% Dow Jones Islamic9.1% S&P Shariah9.1% MSCI Islamic17.7% MSCI Islamic M-Series9.1% FTSE Shariah16.2% |
| Veradermics Inc | UNSCREENED | 2.11% | no in-house ratios for this holding |
| Relay Therapeutics Inc | UNSCREENED | 2.05% | no in-house ratios for this holding |
| Denali Therapeutics Inc | UNSCREENED | 1.94% | no in-house ratios for this holding |
| Amylyx Pharmaceuticals Inc | UNSCREENED | 1.93% | no in-house ratios for this holding |
| IDYA Ideaya Biosciences Inc | NON_COMPLIANT | 1.81% | AAOIFI1.0% Usmani2.4% Dow Jones Islamic1.2% S&P Shariah1.1% MSCI Islamic2.4% MSCI Islamic M-Series1.1% FTSE Shariah0.0% |
| GPCR Structure Therapeutics Inc | NON_COMPLIANT | 1.68% | AAOIFI0.5% Usmani0.5% Dow Jones Islamic0.1% S&P Shariah0.1% MSCI Islamic0.5% MSCI Islamic M-Series0.1% FTSE Shariah0.0% |
| TARS Tarsus Pharmaceuticals Inc | COMPLIANT | 1.64% | AAOIFI2.3% Usmani14.5% Dow Jones Islamic3.8% S&P Shariah4.7% MSCI Islamic14.5% MSCI Islamic M-Series4.7% FTSE Shariah11.9% |
| Celldex Therapeutics Inc | UNSCREENED | 1.60% | no in-house ratios for this holding |
| IMNM Immunome Inc | NON_COMPLIANT | 1.60% | AAOIFI0.5% Usmani2.3% Dow Jones Islamic0.7% S&P Shariah0.9% MSCI Islamic2.3% MSCI Islamic M-Series0.9% FTSE Shariah0.0% |
| Disc Medicine Inc | UNSCREENED | 1.54% | no in-house ratios for this holding |
| Newamsterdam Pharma Co Nv | UNSCREENED | 1.52% | no in-house ratios for this holding |
| Mbx Biosciences Inc | UNSCREENED | 1.50% | no in-house ratios for this holding |
| 9688.HK Zai Lab Ltd | NON_COMPLIANT | 1.42% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| Viridian Therapeutics Inc | UNSCREENED | 1.31% | no in-house ratios for this holding |
| Sellas Life Sciences Group Inc | UNSCREENED | 1.28% | no in-house ratios for this holding |
| BCRX Biocryst Pharmaceuticals Inc | NON_COMPLIANT | 1.27% | AAOIFI21.1% Usmani68.8% Dow Jones Islamic21.3% S&P Shariah23.8% MSCI Islamic68.5% MSCI Islamic M-Series23.8% FTSE Shariah66.9% |
| Vera Therapeutics Inc | UNSCREENED | 1.26% | no in-house ratios for this holding |
| NKTR Nektar Therapeutics | NON_COMPLIANT | 1.24% | AAOIFI6.0% Usmani7.1% Dow Jones Islamic6.7% S&P Shariah9.2% MSCI Islamic7.1% MSCI Islamic M-Series9.2% FTSE Shariah0.0% |
| Rapport Therapeutics Inc | UNSCREENED | 1.19% | no in-house ratios for this holding |
| NUVB Nuvation Bio Inc | NON_COMPLIANT | 1.19% | AAOIFI21.7% Usmani38.6% Dow Jones Islamic20.6% S&P Shariah25.7% MSCI Islamic38.6% MSCI Islamic M-Series25.7% FTSE Shariah36.7% |
| Mineralys Therapeutics Inc | UNSCREENED | 1.16% | no in-house ratios for this holding |
| SRPT Sarepta Therapeutics Inc | NON_COMPLIANT | 1.14% | AAOIFI43.1% Usmani32.8% Dow Jones Islamic21.4% S&P Shariah14.9% MSCI Islamic32.8% MSCI Islamic M-Series14.9% FTSE Shariah26.6% |
| Palvella Therapeutics Inc | UNSCREENED | 1.12% | no in-house ratios for this holding |
| ZBIO Zenas Biopharma Inc | NON_COMPLIANT | 1.05% | AAOIFI3.9% Usmani11.3% Dow Jones Islamic8.0% S&P Shariah— MSCI Islamic11.3% MSCI Islamic M-Series— FTSE Shariah11.2% |
| VCEL Vericel Corp | COMPLIANT | 1.05% | AAOIFI4.0% Usmani18.5% Dow Jones Islamic4.4% S&P Shariah4.4% MSCI Islamic18.4% MSCI Islamic M-Series4.4% FTSE Shariah0.0% |
| Xencor Inc | UNSCREENED | 1.04% | no in-house ratios for this holding |
| AGIO Agios Pharmaceuticals Inc | NON_COMPLIANT | 1.03% | AAOIFI1.4% Usmani2.5% Dow Jones Islamic1.3% S&P Shariah1.3% MSCI Islamic2.5% MSCI Islamic M-Series1.3% FTSE Shariah0.0% |
| KLRA Kailera Therapeutics Inc | NON_COMPLIANT | 1.03% | AAOIFI0.6% Usmani0.9% Dow Jones Islamic— S&P Shariah— MSCI Islamic0.9% MSCI Islamic M-Series— FTSE Shariah0.0% |
| Generate Biomedicines Inc | UNSCREENED | 1.00% | no in-house ratios for this holding |
| STOK Stoke Therapeutics Inc | NON_COMPLIANT | 1.00% | AAOIFI0.1% Usmani0.7% Dow Jones Islamic0.2% S&P Shariah0.3% MSCI Islamic0.7% MSCI Islamic M-Series0.3% FTSE Shariah0.0% |
| LKFT.AS Lakefront Biotherapeutics Nv | NON_COMPLIANT | 0.95% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| IMCR Immunocore Holdings Plc | NON_COMPLIANT | 0.95% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariah— MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| CMPS Compass Pathways Plc | NON_COMPLIANT | 0.94% | AAOIFI4.3% Usmani10.5% Dow Jones Islamic6.8% S&P Shariah7.7% MSCI Islamic10.5% MSCI Islamic M-Series7.7% FTSE Shariah9.8% |
| TSHA Taysha Gene Therapies Inc | NON_COMPLIANT | 0.84% | AAOIFI3.9% Usmani12.5% Dow Jones Islamic5.1% S&P Shariah6.4% MSCI Islamic12.5% MSCI Islamic M-Series6.4% FTSE Shariah10.9% |
| BCAX Bicara Therapeutics Inc | NON_COMPLIANT | 0.78% | AAOIFI0.1% Usmani0.2% Dow Jones Islamic0.1% S&P Shariah— MSCI Islamic0.2% MSCI Islamic M-Series— FTSE Shariah0.0% |
| TYRA Tyra Biosciences Inc | COMPLIANT | 0.77% | AAOIFI0.4% Usmani0.8% Dow Jones Islamic0.5% S&P Shariah0.5% MSCI Islamic0.8% MSCI Islamic M-Series0.5% FTSE Shariah0.0% |
| MAZE Maze Therapeutics Inc | COMPLIANT | 0.76% | AAOIFI3.3% Usmani11.7% Dow Jones Islamic4.7% S&P Shariahfail MSCI Islamic11.7% MSCI Islamic M-Seriesfail FTSE Shariah7.6% |
| AVBP Arrivent Biopharma Inc | NON_COMPLIANT | 0.72% | AAOIFI0.0% Usmani0.1% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.1% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| LBRX Lb Pharmaceuticals Inc | NON_COMPLIANT | 0.70% | AAOIFI0.4% Usmani1.1% Dow Jones Islamic— S&P Shariah— MSCI Islamic1.1% MSCI Islamic M-Series— FTSE Shariah0.0% |
| IMTX Immatics Nv | NON_COMPLIANT | 0.66% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| MGTX Meiragtx Holdings Plc | COMPLIANT | 0.65% | AAOIFI1.4% Usmani2.9% Dow Jones Islamic1.6% S&P Shariah2.0% MSCI Islamic2.9% MSCI Islamic M-Series2.0% FTSE Shariah0.0% |
| Seaport Therapeutics Inc | UNSCREENED | 0.65% | no in-house ratios for this holding |
| Alto Neuroscience Inc | UNSCREENED | 0.64% | no in-house ratios for this holding |
| MNKD Mannkind Corp | NON_COMPLIANT | 0.64% | AAOIFI25.3% Usmani45.8% Dow Jones Islamic23.8% S&P Shariah24.2% MSCI Islamic45.8% MSCI Islamic M-Series24.2% FTSE Shariah44.2% |
| VOR Vor Biopharma Inc | NON_COMPLIANT | 0.62% | AAOIFI0.3% Usmani0.6% Dow Jones Islamic0.9% S&P Shariah1.2% MSCI Islamic0.6% MSCI Islamic M-Series1.2% FTSE Shariah0.0% |
| CRVS Corvus Pharmaceuticals Inc | COMPLIANT | 0.61% | AAOIFI0.1% Usmani0.3% Dow Jones Islamic0.1% S&P Shariah0.1% MSCI Islamic0.3% MSCI Islamic M-Series0.1% FTSE Shariah0.0% |
| KURA Kura Oncology Inc | NON_COMPLIANT | 0.58% | AAOIFI3.8% Usmani4.6% Dow Jones Islamic3.4% S&P Shariah2.6% MSCI Islamic4.6% MSCI Islamic M-Series2.6% FTSE Shariah1.7% |
| CADL Candel Therapeutics Inc | NON_COMPLIANT | 0.49% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| GERN Geron Corp | NON_COMPLIANT | 0.49% | AAOIFI20.0% Usmani23.0% Dow Jones Islamic11.6% S&P Shariah8.9% MSCI Islamic23.0% MSCI Islamic M-Series8.9% FTSE Shariah22.8% |
| Solid Biosciences Inc | UNSCREENED | 0.49% | no in-house ratios for this holding |
| DSGN Design Therapeutics Inc | NON_COMPLIANT | 0.49% | AAOIFI0.4% Usmani1.2% Dow Jones Islamic0.5% S&P Shariah0.6% MSCI Islamic1.2% MSCI Islamic M-Series0.6% FTSE Shariah0.0% |
| WVE Wave Life Sciences Inc | NON_COMPLIANT | 0.48% | AAOIFI3.9% Usmani7.8% Dow Jones Islamic2.9% S&P Shariah3.6% MSCI Islamic7.8% MSCI Islamic M-Series3.6% FTSE Shariah0.0% |
| OLMA Olema Pharmaceuticals Inc | NON_COMPLIANT | 0.47% | AAOIFI0.1% Usmani0.1% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.1% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| Theravance Biopharma Inc | UNSCREENED | 0.45% | no in-house ratios for this holding |
| RIGL Rigel Pharmaceuticals Inc | COMPLIANT | 0.44% | AAOIFI5.0% Usmani8.8% Dow Jones Islamic9.0% S&P Shariah11.3% MSCI Islamic8.8% MSCI Islamic M-Series11.3% FTSE Shariah8.6% |
| ACRS Aclaris Therapeutics Inc | NON_COMPLIANT | 0.44% | AAOIFI0.3% Usmani0.8% Dow Jones Islamic0.4% S&P Shariah0.6% MSCI Islamic0.8% MSCI Islamic M-Series0.6% FTSE Shariah0.0% |
| Spyglass Pharma Inc | UNSCREENED | 0.43% | no in-house ratios for this holding |
| CLYM Climb Bio Inc | NON_COMPLIANT | 0.41% | AAOIFI0.2% Usmani0.5% Dow Jones Islamic0.3% S&P Shariah0.4% MSCI Islamic0.5% MSCI Islamic M-Series0.4% FTSE Shariah0.0% |
| FDMT 4d Molecular Therapeutics Inc | NON_COMPLIANT | 0.38% | AAOIFI6.2% Usmani9.0% Dow Jones Islamic9.4% S&P Shariah6.5% MSCI Islamic9.0% MSCI Islamic M-Series6.5% FTSE Shariah4.6% |
| OCSAW Oculis Holding Ag | NON_COMPLIANT | 0.36% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic— S&P Shariah— MSCI Islamic0.0% MSCI Islamic M-Series— FTSE Shariah0.0% |
| ALLO Allogene Therapeutics Inc | NON_COMPLIANT | 0.36% | AAOIFI26.5% Usmani15.0% Dow Jones Islamic17.8% S&P Shariah16.2% MSCI Islamic15.0% MSCI Islamic M-Series16.2% FTSE Shariah0.0% |
| Agomab Therapeutics Nv | UNSCREENED | 0.33% | no in-house ratios for this holding |
| ALT Altimmune Inc | NON_COMPLIANT | 0.31% | AAOIFI11.3% Usmani7.3% Dow Jones Islamic7.7% S&P Shariah7.6% MSCI Islamic7.3% MSCI Islamic M-Series7.6% FTSE Shariah7.1% |
| NGNE Neurogene Inc | NON_COMPLIANT | 0.30% | AAOIFI1.6% Usmani2.0% Dow Jones Islamic2.0% S&P Shariah2.0% MSCI Islamic2.0% MSCI Islamic M-Series2.0% FTSE Shariah0.0% |
| DCTH Delcath Systems Inc | COMPLIANT | 0.29% | AAOIFIpass Usmanifail Dow Jones Islamicpass S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahfail |
| EIKN Eikon Therapeutics Inc | NON_COMPLIANT | 0.29% | AAOIFI85.5% Usmani35.3% Dow Jones Islamic— S&P Shariah— MSCI Islamic35.3% MSCI Islamic M-Series— FTSE Shariah0.0% |
| TECX Tectonic Therapeutic Inc | NON_COMPLIANT | 0.29% | AAOIFI0.7% Usmani1.9% Dow Jones Islamic0.9% S&P Shariah1.2% MSCI Islamic1.8% MSCI Islamic M-Series1.2% FTSE Shariah0.0% |
| FLGT Fulgent Genetics Inc | NON_COMPLIANT | 0.28% | AAOIFI1.2% Usmani0.8% Dow Jones Islamic1.4% S&P Shariah1.3% MSCI Islamic0.8% MSCI Islamic M-Series1.3% FTSE Shariah0.0% |
| CTNM Contineum Therapeutics Inc | NON_COMPLIANT | 0.27% | AAOIFI1.7% Usmani2.4% Dow Jones Islamic2.5% S&P Shariah2.3% MSCI Islamic2.4% MSCI Islamic M-Series2.3% FTSE Shariah0.0% |
| Zura Bio Ltd | UNSCREENED | 0.27% | no in-house ratios for this holding |
| RLMD Relmada Therapeutics Inc | NON_COMPLIANT | 0.24% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| EVMN Evommune Inc | NON_COMPLIANT | 0.24% | AAOIFI2.5% Usmani2.9% Dow Jones Islamicfail S&P Shariahfail MSCI Islamic2.7% MSCI Islamic M-Seriesfail FTSE Shariah0.0% |
| Rezolute Inc | UNSCREENED | 0.23% | no in-house ratios for this holding |
| CMPX Compass Therapeutics Inc | NON_COMPLIANT | 0.22% | AAOIFI7.8% Usmani5.3% Dow Jones Islamic1.9% S&P Shariah2.3% MSCI Islamic5.3% MSCI Islamic M-Series2.3% FTSE Shariah0.0% |
| ARCT Arcturus Therapeutics Holdings Inc | NON_COMPLIANT | 0.22% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| CCCC C4 Therapeutics Inc | NON_COMPLIANT | 0.21% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| Enanta Pharmaceuticals Inc | UNSCREENED | 0.20% | no in-house ratios for this holding |
| XFOR X4 Pharmaceuticals Inc | NON_COMPLIANT | 0.20% | AAOIFI20.0% Usmani29.8% Dow Jones Islamic10.3% S&P Shariah5.3% MSCI Islamic29.8% MSCI Islamic M-Series5.3% FTSE Shariah29.6% |
| UPB Upstream Bio Inc | NON_COMPLIANT | 0.19% | AAOIFI0.4% Usmani0.3% Dow Jones Islamic0.1% S&P Shariah— MSCI Islamic0.3% MSCI Islamic M-Series— FTSE Shariah0.0% |
| Immuneering Corp | UNSCREENED | 0.17% | no in-house ratios for this holding |
| IKT Inhibikase Therapeutics Inc | NON_COMPLIANT | 0.16% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| SABS Sab Biotherapeutics Inc | NON_COMPLIANT | 0.15% | AAOIFI0.6% Usmani2.2% Dow Jones Islamic1.8% S&P Shariah2.3% MSCI Islamic0.8% MSCI Islamic M-Series2.3% FTSE Shariah0.0% |
| SION Sionna Therapeutics Inc | NON_COMPLIANT | 0.14% | AAOIFI5.1% Usmani2.9% Dow Jones Islamic0.7% S&P Shariah— MSCI Islamic2.9% MSCI Islamic M-Series— FTSE Shariah0.0% |
| Anavex Life Sciences Corp | UNSCREENED | 0.13% | no in-house ratios for this holding |
| FULC Fulcrum Therapeutics Inc | NON_COMPLIANT | 0.13% | AAOIFI2.4% Usmani2.2% Dow Jones Islamic1.9% S&P Shariah1.8% MSCI Islamic2.2% MSCI Islamic M-Series1.8% FTSE Shariah0.0% |
| MGNX Macrogenics Inc | NON_COMPLIANT | 0.13% | AAOIFI26.6% Usmani10.9% Dow Jones Islamic21.5% S&P Shariah12.1% MSCI Islamic10.9% MSCI Islamic M-Series12.1% FTSE Shariah0.0% |
| AKBA Akebia Therapeutics Inc | NON_COMPLIANT | 0.13% | AAOIFI45.9% Usmani17.7% Dow Jones Islamic12.5% S&P Shariah14.6% MSCI Islamic17.7% MSCI Islamic M-Series14.6% FTSE Shariah14.7% |
| TARA Protara Therapeutics Inc | NON_COMPLIANT | 0.11% | AAOIFI1.6% Usmani1.6% Dow Jones Islamic1.4% S&P Shariah1.8% MSCI Islamic1.6% MSCI Islamic M-Series1.8% FTSE Shariah0.0% |
| IMUX Immunic Inc | NON_COMPLIANT | 0.11% | AAOIFI0.6% Usmani0.4% Dow Jones Islamic0.5% S&P Shariah0.5% MSCI Islamic0.4% MSCI Islamic M-Series0.5% FTSE Shariah0.0% |
| NBP Novabridge Biosciences | NON_COMPLIANT | 0.11% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariah— MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| 50BA.SG Bicycle Therapeutics Plc | NON_COMPLIANT | 0.11% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| TENX Tenax Therapeutics Inc | NON_COMPLIANT | 0.03% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| State Street Institutional Treasury Plus Money Market Fund | UNSCREENED | 0.02% | no in-house ratios for this holding |
| NOVO-B.CO Novo Nordisk A/s | COMPLIANT | 0.00% | AAOIFIpass Usmanipass Dow Jones Islamicpass S&P Shariahpass MSCI Islamicpass MSCI Islamic M-Seriespass FTSE Shariahpass |
| AZN Astrazeneca Plc | COMPLIANT | 0.00% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| Chinook Therapeutics Inc | UNSCREENED | 0.00% | no in-house ratios for this holding |
| OABI Omniab Inc | NON_COMPLIANT | 0.00% | AAOIFI2.5% Usmani6.2% Dow Jones Islamic5.3% S&P Shariah4.4% MSCI Islamic6.2% MSCI Islamic M-Series4.4% FTSE Shariah0.0% |
| OABI Omniab Inc | NON_COMPLIANT | 0.00% | AAOIFI2.5% Usmani6.2% Dow Jones Islamic5.3% S&P Shariah4.4% MSCI Islamic6.2% MSCI Islamic M-Series4.4% FTSE Shariah0.0% |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
The published standards disagree about this fund by 13 points of portfolio weight — 13.2% of it passes S&P Shariah, 0.6% passes MSCI Islamic. Which number is yours depends on which standard you follow.
These bars are the financial-ratio result under each standard — debt, receivables and interest income. They do not screen what the business does, so a holding can pass every ratio here and still be questionable or non-compliant on activity. The blended verdict above accounts for both.
ratios pass on 10.8% ratios fail on 32.5% 56.7% not rated under AAOIFI
ratios pass on 1.7% ratios fail on 43.9% 54.4% not rated under Usmani
ratios pass on 12.8% ratios fail on 27.3% 59.9% not rated under Dow Jones Islamic
ratios pass on 13.2% ratios fail on 17.6% 69.3% not rated under S&P Shariah
ratios pass on 0.6% ratios fail on 44.9% 54.5% not rated under MSCI Islamic
ratios pass on 11.3% ratios fail on 25.7% 63.1% not rated under MSCI Islamic M-Series
ratios pass on 1.7% ratios fail on 43.9% 54.4% not rated under FTSE Shariah
71 of 110 listed holdings carry our own per-methodology verdicts (47% of weight). The rest hold a provider verdict with no methodology breakdown, and are counted as rated by none. Of those, 59 (42% of weight) also carry the underlying debt ratio; the rest show a verdict without the figure behind it.
| Non-compliant holding | Weight |
|---|---|
| DYN Dyne Therapeutics Inc | 2.16% |
| IDYA Ideaya Biosciences Inc | 1.81% |
| GPCR Structure Therapeutics Inc | 1.68% |
| IMNM Immunome Inc | 1.60% |
| 9688.HK Zai Lab Ltd | 1.42% |
| BCRX Biocryst Pharmaceuticals Inc | 1.27% |
| NKTR Nektar Therapeutics | 1.24% |
| NUVB Nuvation Bio Inc | 1.19% |
| SRPT Sarepta Therapeutics Inc | 1.14% |
| ZBIO Zenas Biopharma Inc | 1.05% |
Methodology breakdown computing — it will appear here on its own.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
ALPS Medical Breakthroughs ETF (SBIO) is currently considered not halal (non-compliant), per our own look-through to its filed holdings. See its filed holdings and the weight breakdown below for the reasoning.
🕌 In-house Compliance Research
Computing the full ratio and business-activity breakdown for SBIO — this runs off the critical path so the page paints first. It will appear here on its own.
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Ken Griffin | Citadel Advisors | $1M | 0.0% | 2026-09-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 43.30 | NEUTRAL |
| Stochastic %K (14) | 12.96 | BUY |
| CCI (20) | -88.91 | NEUTRAL |
| Williams %R (14) | -87.04 | BUY |
| MACD (12,26,9) | 0.06 | BUY |
| ROC (10) | -1.54 | SELL |
| Momentum (10) | -0.84 | SELL |
| EMA (10) | 55.22 | SELL |
| SMA (10) | 55.68 | SELL |
| EMA (20) | 55.31 | SELL |
| SMA (20) | 55.17 | SELL |
| EMA (30) | 55.76 | SELL |
| SMA (30) | 54.41 | SELL |
| EMA (50) | 56.98 | SELL |
| SMA (50) | 56.77 | SELL |
| EMA (100) | 58.20 | SELL |
| SMA (100) | 61.59 | SELL |
| EMA (200) | 56.00 | SELL |
| SMA (200) | 57.23 | SELL |
About ALPS Medical Breakthroughs ETF
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
Background via Yahoo Finance — informational, not part of the verdict.
Weak — low conviction, small size or skip
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | RANGING | 42 |
| 🕐 1H | RANGING | 51 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | BULLISH | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is a fund screened on its name?
No. HTR reads the fund's filed holdings and screens each one, then reports the result by weight. A fund marketed as Islamic still gets the same look-through as any other.
What does unrated weight mean?
It is the share of the fund whose holdings HTR cannot cover far enough to rate. It is reported as unrated rather than counted as compliant, because a holding nobody screened should not look like one that passed.
Does the issuer's board make it compliant?
It matters, and it is noted, but it does not replace the look-through. The board's judgement and the holdings screen are shown separately so you can see when they agree and when they do not.
How often is this re-screened?
When the fund files new holdings, and on a rolling basis besides. The date on the verdict above is the last time this fund was actually recomputed.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-11-10 · Asset managers net 914130 (-14454)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.